SAFETY AND EFFICACY OF DRUG ELUTING STENTS AND BARE METAL STENTS FOR SAPHENOUS VEIN GRAFT INTERVENTIONS- COMPREHENSIVE META-ANALYSIS OF RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES COMPRISING 7994 PATIENTS  by Hakeem, Abdul et al.
    
 i2 SUMMIT   
A190.E1779 
JACC March 9, 2010
Volume 55, issue 10A
SAFETY AND EFFICACY OF DRUG ELUTING STENTS AND BARE METAL STENTS FOR SAPHENOUS 
VEIN GRAFT INTERVENTIONS- COMPREHENSIVE META-ANALYSIS OF RANDOMIZED TRIALS AND 
OBSERVATIONAL STUDIES COMPRISING 7994 PATIENTS
i2 Poster Contributions
Georgia World Congress Center, Hall B5
Sunday, March 14, 2010, 9:30 a.m.-10:30 a.m.
Session Title: DES I and Acute Coronary Syndromes
Abstract Category: PCI - DES
Presentation Number: 2501-509
Authors: Abdul Hakeem, Siddharth Munsif, Sabha Bhatti, Mohamed Effat, Massoud Leesar, Tarek Helmy, Imran Arif, University of Cincinnati, College 
of Medicine, Cincinnati, OH
Background: Saphenous vein graft (SVG) lesions are amongst the most challenging PCI lesions. It remains unknown whether DES are superior 
to BMS for such lesions. Our objective is to determine the safety and efficacy of DES as compared to BMS in SVG by performing a meta analysis of 
randomized clinical trials (RCTs) and observational studies (OS).
Results: 3 RCTs and 26 OS with 4187 patients in the DES arm and 3807 patients in the BMS group formed the data set. Mean follow-up (FU) 
duration was 21+/-11 months (6-48 months). In RCTs, DES were associated with no significant differences in mortality (Risk ratio [RR], 1.97; 95% 
confidence interval [CI], 0.17 to 23; P=0.58) or MI (RR= 1.24; 95% CI, 0.3 -5.5; P=0.78).In the pooled population, MACE events were 19% in 
DES and 28% in BMS [RR 0.7 (0.6, 0.8) p<0.00001] (Figure). This effect on MACE persisted in studies with >2 years FU [RR of 0.77 (0.65,0.91) 
p=0.003]. Death rate was 7.2% in DES and 8.9% in BMS [RR 0.8 (0.69, 0.95) p=0.01], MI rate was 5.7% in DES and 7.5% in BMS [RR 0.73 (0.57, 
0.94) p=0.01]. TVR rate 12.2% in DES and 17.7% in BMS [RR 0.71 (0.59, 0.85) p=0.0002]. Stent thrombosis was 1% in DES and 2 % in BMS [RR 
0.6 (0.34, 1.07) p= 0.09].
Conclusions: In RCTs, use of DES for SVG lesions did not increase the risk of death or MI . In real-world observational studies, 
with greater numbers of patients but limited by various biases and confounders, DES use for SVG was associated with reduced 
death, MI & TVR compared to BMS. The preponderance of data suggests that DES is safe and efficacious for SVG lesions
